News | October 11, 2021
Sai Life Sciences presents its midterm report
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
The company plans to expand its portfolio in regulated markets aggressively
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
Now all districts of the country will have commissioned PSA Oxygen plants
The initiative will create an integrated network of Critical Care Units (CCUs) across the Apollo Hospitals network but also in partnership with non-Apollo units in India and overseas
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
Subscribe To Our Newsletter & Stay Updated
